Ardena Supports Topas Therapeutics’ Nanoparticle-Based Immune Tolerance Therapies Advancing to Clinical Development
Ghent, Belgium, 13th June 2025 A suite of nanoparticle-based immunotherapies developed by Topas Therapeutics has successfully progressed into clinical trials, supported end-to-end regarding Chemistry, Manufacturing, and Control (CMC) by Ardena, a specialist partner in the development and manufacturing of complex formulations and precision medicines. Topas Therapeutics, based in Hamburg, Germany, is pioneering a highly differentiated […]